MVA85A

MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the old TB vaccine called BCG.^[1] Phase I clinical trials have been completed and phase II clinical trials are currently underway in South Africa with the aim of achieving a product licence by 2010.^[2]

References

1. ^ McShane H, Pathan AA, Sander CR, et al. (2004). "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-mycrobial immunity in humans". Nat Med 10: 1240–44.
2. ^ Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H (2006). "Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design". Lancet Infect Dis 6 (8): 522-8. PMID 16870530.